Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St rises as softer jobs data calms rate-hike fears
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Nektar Therapeutics (NKTR) Tops Q4 EPS by 2c
March 1, 2016 4:55 PM ESTNektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $39.4 million versus the consensus estimate of $28.82 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More